JP2016509023A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016509023A5 JP2016509023A5 JP2015558092A JP2015558092A JP2016509023A5 JP 2016509023 A5 JP2016509023 A5 JP 2016509023A5 JP 2015558092 A JP2015558092 A JP 2015558092A JP 2015558092 A JP2015558092 A JP 2015558092A JP 2016509023 A5 JP2016509023 A5 JP 2016509023A5
- Authority
- JP
- Japan
- Prior art keywords
- fragment
- polypeptide
- variant
- npp4
- npp1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012634 fragment Substances 0.000 claims description 190
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 152
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 152
- 229920001184 polypeptide Polymers 0.000 claims description 147
- 101150011046 NPP1 gene Proteins 0.000 claims description 69
- 101100080092 Phytophthora capsici NLP1 gene Proteins 0.000 claims description 69
- 230000000694 effects Effects 0.000 claims description 38
- 239000000203 mixture Substances 0.000 claims description 32
- 230000007062 hydrolysis Effects 0.000 claims description 31
- 238000006460 hydrolysis reaction Methods 0.000 claims description 31
- 230000035772 mutation Effects 0.000 claims description 24
- 108010064470 polyaspartate Proteins 0.000 claims description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 16
- QCICUPZZLIQAPA-XPWFQUROSA-N P(1),P(3)-bis(5'-adenosyl) triphosphate Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]([C@H](O)[C@@H]1O)O[C@@H]1COP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]([C@@H](O)[C@H]1O)O[C@H]1N1C(N=CN=C2N)=C2N=C1 QCICUPZZLIQAPA-XPWFQUROSA-N 0.000 claims description 12
- 239000012190 activator Substances 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 12
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 8
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 claims description 8
- 235000011180 diphosphates Nutrition 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 8
- 208000035475 disorder Diseases 0.000 claims description 8
- 229920000805 Polyaspartic acid Polymers 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 5
- 239000000816 peptidomimetic Substances 0.000 claims description 5
- 235000018102 proteins Nutrition 0.000 claims description 5
- 102000004169 proteins and genes Human genes 0.000 claims description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 5
- -1 small molecule chemical compounds Chemical class 0.000 claims description 5
- MSYGAHOHLUJIKV-UHFFFAOYSA-N 3,5-dimethyl-1-(3-nitrophenyl)-1h-pyrazole-4-carboxylic acid ethyl ester Chemical compound CC1=C(C(=O)OCC)C(C)=NN1C1=CC=CC([N+]([O-])=O)=C1 MSYGAHOHLUJIKV-UHFFFAOYSA-N 0.000 claims description 4
- 208000004434 Calcinosis Diseases 0.000 claims description 4
- 101001117086 Dictyostelium discoideum cAMP/cGMP-dependent 3',5'-cAMP/cGMP phosphodiesterase A Proteins 0.000 claims description 4
- 208000034970 Heterotopic Ossification Diseases 0.000 claims description 4
- 101150071357 NPP2 gene Proteins 0.000 claims description 4
- 101100080097 Phytophthora capsici NLP2 gene Proteins 0.000 claims description 4
- 102000011017 Type 4 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 claims description 4
- 108010037584 Type 4 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 claims description 4
- 230000002308 calcification Effects 0.000 claims description 4
- 230000001575 pathological effect Effects 0.000 claims description 4
- 239000000758 substrate Substances 0.000 claims description 4
- 208000037260 Atherosclerotic Plaque Diseases 0.000 claims description 3
- 235000008733 Citrus aurantifolia Nutrition 0.000 claims description 3
- 208000009469 Ossification of Posterior Longitudinal Ligament Diseases 0.000 claims description 3
- 235000011941 Tilia x europaea Nutrition 0.000 claims description 3
- 208000005475 Vascular calcification Diseases 0.000 claims description 3
- 230000003213 activating effect Effects 0.000 claims description 3
- 208000011111 hypophosphatemic rickets Diseases 0.000 claims description 3
- 239000004571 lime Substances 0.000 claims description 3
- 201000002044 ossification of the posterior longitudinal ligament of spine Diseases 0.000 claims description 3
- 208000001040 ossification of the posterior longitudinal ligament of the spine Diseases 0.000 claims description 3
- 201000008482 osteoarthritis Diseases 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 16
- 239000013543 active substance Substances 0.000 claims 4
- 230000004913 activation Effects 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 230000003301 hydrolyzing effect Effects 0.000 claims 1
- 102100021961 Bis(5'-adenosyl)-triphosphatase ENPP4 Human genes 0.000 description 55
- 101000897056 Homo sapiens Bis(5'-adenosyl)-triphosphatase ENPP4 Proteins 0.000 description 55
- 238000000034 method Methods 0.000 description 37
- CKLJMWTZIZZHCS-REOHCLBHSA-L aspartate group Chemical group N[C@@H](CC(=O)[O-])C(=O)[O-] CKLJMWTZIZZHCS-REOHCLBHSA-L 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019135862A JP6944977B2 (ja) | 2013-02-13 | 2019-07-24 | 病的な石灰化および骨化を治療するための組成物および方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361764297P | 2013-02-13 | 2013-02-13 | |
| US61/764,297 | 2013-02-13 | ||
| US201361904786P | 2013-11-15 | 2013-11-15 | |
| US61/904,786 | 2013-11-15 | ||
| PCT/US2014/015945 WO2014126965A2 (en) | 2013-02-13 | 2014-02-12 | Compositions and methods for treating pathological calcification and ossification |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019135862A Division JP6944977B2 (ja) | 2013-02-13 | 2019-07-24 | 病的な石灰化および骨化を治療するための組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016509023A JP2016509023A (ja) | 2016-03-24 |
| JP2016509023A5 true JP2016509023A5 (cg-RX-API-DMAC7.html) | 2017-02-16 |
| JP6894664B2 JP6894664B2 (ja) | 2021-06-30 |
Family
ID=51354667
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015558092A Active JP6894664B2 (ja) | 2013-02-13 | 2014-02-12 | 病的な石灰化および骨化を治療するための組成物および方法 |
| JP2019135862A Active JP6944977B2 (ja) | 2013-02-13 | 2019-07-24 | 病的な石灰化および骨化を治療するための組成物および方法 |
| JP2021104071A Active JP7420766B2 (ja) | 2013-02-13 | 2021-06-23 | 病的な石灰化および骨化を治療するための組成物および方法 |
| JP2024002210A Pending JP2024026704A (ja) | 2013-02-13 | 2024-01-11 | 病的な石灰化および骨化を治療するための組成物および方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019135862A Active JP6944977B2 (ja) | 2013-02-13 | 2019-07-24 | 病的な石灰化および骨化を治療するための組成物および方法 |
| JP2021104071A Active JP7420766B2 (ja) | 2013-02-13 | 2021-06-23 | 病的な石灰化および骨化を治療するための組成物および方法 |
| JP2024002210A Pending JP2024026704A (ja) | 2013-02-13 | 2024-01-11 | 病的な石灰化および骨化を治療するための組成物および方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (7) | US9744219B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP2956163B1 (cg-RX-API-DMAC7.html) |
| JP (4) | JP6894664B2 (cg-RX-API-DMAC7.html) |
| ES (1) | ES3014398T3 (cg-RX-API-DMAC7.html) |
| PL (1) | PL2956163T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2014126965A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2956163B1 (en) * | 2013-02-13 | 2024-11-27 | Yale University | Compositions for treating pathological calcification and ossification |
| BR112017012928A2 (pt) | 2014-12-19 | 2018-05-15 | Alexion Pharma Inc | uso de um ectonucleotídeo pirofosfatase fosfodiesterase (npp1); uso de uma composição farmacêutica; e uso de um snpp1 humano recombinante isolado, fragmento ou proteína de fusão deste |
| CA3176123A1 (en) * | 2015-05-19 | 2016-11-24 | Yale University | Compositions for treating pathological calcification conditions, and methods using same |
| JP2018537093A (ja) | 2015-11-20 | 2018-12-20 | イエール ユニバーシティ | 異所性石灰化障害を治療するための組成物およびそれを使用する方法 |
| US11364284B2 (en) | 2016-06-16 | 2022-06-21 | Inozyme Pharma, Inc. | Methods of treating myointimal proliferation |
| BR112019002355A2 (pt) * | 2016-08-05 | 2019-07-16 | Yale University | composições e métodos para prevenção de acidente vascular cerebral em pacientes pediátricos com anemia falciforme |
| WO2019067502A1 (en) | 2017-09-27 | 2019-04-04 | Alexion Pharmaceuticals, Inc. | METHODS FOR IMPROVING CARDIOVASCULAR FUNCTION AND TREATING CARDIOVASCULAR DISEASE USING RECOMBINANT ECTO-NUCLEOTIDE PYROPHOSPHATASE / PHOSPHODIESTERASE |
| CA3099266A1 (en) | 2018-05-08 | 2019-11-14 | Yale University | Compositions and methods for reducing progression of nephrolithiasis |
| CN112930397B (zh) * | 2018-08-31 | 2025-05-09 | 耶鲁大学 | Enpp1多肽及其使用方法 |
| EP4162036A1 (en) | 2020-06-09 | 2023-04-12 | Inozyme Pharma, Inc. | Soluble enpp1 or enpp3 proteins and uses thereof |
| CN116322742A (zh) * | 2020-07-02 | 2023-06-23 | 依诺兹梅制药公司 | 用于治疗同种异体移植物血管病、烟雾病、烟雾病综合征和内膜增殖的组合物和方法 |
| WO2022076848A1 (en) * | 2020-10-08 | 2022-04-14 | Inozyme Pharma, Inc. | Liver specific production of enpp1 or enpp3 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5023243A (en) | 1981-10-23 | 1991-06-11 | Molecular Biosystems, Inc. | Oligonucleotide therapeutic agent and method of making same |
| US5190931A (en) | 1983-10-20 | 1993-03-02 | The Research Foundation Of State University Of New York | Regulation of gene expression by employing translational inhibition of MRNA utilizing interfering complementary MRNA |
| US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
| US5168053A (en) | 1989-03-24 | 1992-12-01 | Yale University | Cleavage of targeted RNA by RNAase P |
| US6156501A (en) | 1993-10-26 | 2000-12-05 | Affymetrix, Inc. | Arrays of modified nucleic acid probes and methods of use |
| US6043056A (en) | 1998-11-06 | 2000-03-28 | Incyte Pharmaceuticals, Inc. | Cell surface glycoproteins |
| AU2002258592A1 (en) | 2001-03-23 | 2002-11-25 | The Burnham Institute | Compositions and methods for modulating bone mineral deposition |
| US7888372B2 (en) | 2001-03-23 | 2011-02-15 | National Institutes Of Health (Nih) | Compositions and methods for modulating bone mineral deposition |
| US20070015145A1 (en) | 2001-08-14 | 2007-01-18 | Clifford Woolf | Nucleic acid and amino acid sequences involved in pain |
| WO2003072593A2 (en) | 2002-02-21 | 2003-09-04 | University Of Virginia Patent Foundation | Bone targeting peptides |
| GB0803352D0 (en) | 2008-02-22 | 2008-04-02 | Ntnu Technology Transfer As | Oligopeptidic compounds and uses thereof |
| US8846603B2 (en) | 2010-03-12 | 2014-09-30 | Synageva Biopharma Corp. | NPP1 fusion proteins |
| AU2011362576B2 (en) | 2011-03-11 | 2017-06-08 | Alexion Pharmaceuticals, Inc. | NPP1 fusion proteins |
| EP2956163B1 (en) | 2013-02-13 | 2024-11-27 | Yale University | Compositions for treating pathological calcification and ossification |
| BR112017012928A2 (pt) * | 2014-12-19 | 2018-05-15 | Alexion Pharma Inc | uso de um ectonucleotídeo pirofosfatase fosfodiesterase (npp1); uso de uma composição farmacêutica; e uso de um snpp1 humano recombinante isolado, fragmento ou proteína de fusão deste |
| CA3176123A1 (en) | 2015-05-19 | 2016-11-24 | Yale University | Compositions for treating pathological calcification conditions, and methods using same |
-
2014
- 2014-02-12 EP EP14751154.7A patent/EP2956163B1/en active Active
- 2014-02-12 JP JP2015558092A patent/JP6894664B2/ja active Active
- 2014-02-12 ES ES14751154T patent/ES3014398T3/es active Active
- 2014-02-12 US US14/765,514 patent/US9744219B2/en active Active
- 2014-02-12 WO PCT/US2014/015945 patent/WO2014126965A2/en not_active Ceased
- 2014-02-12 PL PL14751154.7T patent/PL2956163T3/pl unknown
- 2014-02-12 EP EP24215211.4A patent/EP4523757A3/en active Pending
-
2017
- 2017-03-22 US US15/466,401 patent/US9913881B2/en active Active
- 2017-08-08 US US15/671,287 patent/US20170333533A1/en not_active Abandoned
- 2017-08-25 US US15/686,972 patent/US10052367B2/en active Active
-
2018
- 2018-07-12 US US16/033,948 patent/US10624958B2/en active Active
-
2019
- 2019-07-24 JP JP2019135862A patent/JP6944977B2/ja active Active
-
2020
- 2020-03-09 US US16/813,315 patent/US11266722B2/en active Active
-
2021
- 2021-06-23 JP JP2021104071A patent/JP7420766B2/ja active Active
-
2022
- 2022-01-28 US US17/587,253 patent/US20220152163A1/en active Pending
-
2024
- 2024-01-11 JP JP2024002210A patent/JP2024026704A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016509023A5 (cg-RX-API-DMAC7.html) | ||
| JP7320571B2 (ja) | 筋消耗疾患治療用の新規なハイブリッドａｃｔｒｉｉｂリガンド捕集タンパク質 | |
| US20220332791A1 (en) | Methods for treating muscle wasting and bone disease using novel hybrid actriib ligand trap proteins | |
| JP7715635B2 (ja) | イズロン酸２－スルファターゼを含むタンパク質分子の製剤 | |
| TWI573806B (zh) | 生物活性胜肽 | |
| KR20190104958A (ko) | 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체의 지속형 결합체 | |
| RU2017144183A (ru) | Композиции для лечения патологических состояний кальцификации и способы их применения | |
| AU2014293386B2 (en) | Cyclic polypeptides for the treatment of heart failure | |
| KR102461538B1 (ko) | 인플루엔자 바이러스 백신 및 이의 용도 | |
| JP2016527249A (ja) | 合成アペリンポリペプチドのバイオコンジュゲート | |
| US20250325469A1 (en) | Inhibitors of atp synthase - cosmetic and therapeutic uses | |
| US20240150736A1 (en) | Fusion proteins comprising sulfoglucosamine sulfohydrolase enzymes and methods thereof | |
| TW201425339A (zh) | 用於治療心臟衰竭之合成線狀愛帕琳（ａｐｅｌｉｎ）模擬物 | |
| WO2008047370A3 (en) | Compositions and methods for inducing angiogenesis | |
| JP2013535965A5 (cg-RX-API-DMAC7.html) | ||
| JP2008531463A5 (cg-RX-API-DMAC7.html) | ||
| JP2017007949A (ja) | 高血圧症の予防又は治療用医薬 | |
| CN117651564A (zh) | 脑血管事件和神经系统疾病的治疗 | |
| Balboni et al. | Influence of the side chain next to C-terminal benzimidazole in opioid pseudopeptides containing the Dmt-Tic pharmacophore | |
| RU2793631C2 (ru) | Слитый белок, содержащий варианты человеческого белка lefty а, и его применение | |
| TW202034940A (zh) | 包含人類Lefty A蛋白變體的融合蛋白及其用途 | |
| ES2353479T3 (es) | Moduladores de il-32. | |
| WO2016011003A1 (en) | TGFβ TYPE II-TYPE III RECEPTOR FUSIONS | |
| JP7756367B2 (ja) | 変異型ａｃｅ２タンパク質 | |
| US20050277575A1 (en) | Therapeutic compositions and methods for treating diseases that involve angiogenesis |